Antibiotics Impact on Healthy Subjects
Trial Summary
What is the purpose of this trial?
More than 250 million courses of antibiotics are prescribed annually in the ambulatory care setting in the United States alone, including more than 40 million in children under 18 years of age. The perception that antibiotic use has minimal attendant adverse side effects contributes to the over-utilization of antibiotics in clinical circumstances when they are not strictly indicated. We have learned much about the human microbiome. The emerging view is of profound life-long bi-directional interactions between our microbiota and our cells. Perturbations in the microbiota affect metabolic, immune, and cognitive physiology in experimental animal models. When a person takes an antibiotic, the antibiotic diffuses via the blood into all body compartments, selecting for resistance. We propose to examine the effects of two commonly used antibiotics (the beta-lactam, amoxicillin and the macrolide azithromycin) on human microbial populations and on metabolic and immune physiology, studying healthy human volunteers in a randomized controlled clinical trial at the NIH Clinical Center. Our hypothesis is that in addition to acutely perturbing the human microbiome, these agents will have measurable metabolic and immunologic effects, with residual effects in the weeks that follow. To test this hypothesis, we will assess the effects of a brief therapeutic course of antibiotics on microbiome and metagenome composition. After an initial evaluation period, antibiotics will be given for 7 days or 5 days (depending on the antibiotic), and there will be a post-treatment evaluation. A control group will receive no drug intervention. Specimens will be obtained from multiple sites at each of 10 time points occurring before, during, and after antibiotic administration, and used for estimating bacterial and fungal composition and gene content. We will also assess the effects of the antibiotic course on markers of innate and adaptive immunity as well as markers of metabolic and hormonal physiology. A subgroup of subjects will be studied in the clinical center metabolic chamber to assess 24-hour energy expenditure and its components (sleeping, diet-induced, and activity energy expenditure), as well as macronutrient oxidation rates (carbohydrate, fat, and protein), during 3 of the 10 study visits. In addition to the primary data analyses, we will build a model that integrates the temporal data to begin to understand the complex intertwined physiology between microbiome and host.
Will I have to stop taking my current medications?
The trial requires that participants have not used certain medications, like antibiotics, antifungals, antivirals, corticosteroids, and others, within the last 6 months. If you are currently taking any of these, you would need to stop and wait for the specified period before joining the trial.
What data supports the effectiveness of the drug amoxicillin and azithromycin?
Research shows that azithromycin is highly effective in treating lower respiratory infections, with a success rate of over 93% in some cases. Additionally, both amoxicillin and azithromycin have been effective in treating ear, nose, and throat infections, as well as preventing recurrent ear infections.12345
Is it safe for healthy people to take antibiotics like Amoxicillin and Azithromycin?
Antibiotics like Amoxicillin and Azithromycin are generally considered safe, but they can cause side effects such as stomach upset and, in rare cases, more serious issues like allergic reactions or gait disturbances. Most side effects are mild and temporary, but it's important to monitor for any unusual symptoms.678910
How does the drug Amoxicillin and Azithromycin differ from other treatments?
Amoxicillin and Azithromycin are antibiotics that may have unique effects on weight gain, as seen in studies where Amoxicillin promoted short-term weight gain in children. Azithromycin is well-tolerated with fewer side effects compared to other antibiotics, but it has been linked to an increased risk of cardiovascular death in some cases.1112131415
Research Team
Christa S Zerbe, M.D.
Principal Investigator
National Institute of Allergy and Infectious Diseases (NIAID)
Eligibility Criteria
Healthy adults aged 18-50 who can swallow capsules and comply with study procedures. Participants must be willing to allow storage of their biological samples but cannot have used certain medications or substances in the past months, including systemic antibiotics, steroids, probiotics, antacids, laxatives, and more. Smokers and those with a range of health conditions or recent significant weight changes are excluded.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either amoxicillin for 7 days or azithromycin for 5 days, with a control group receiving no drug intervention
Post-treatment Evaluation
Participants are evaluated for changes in microbiome, immune, and metabolic parameters after antibiotic administration
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Amoxicillin
- Azithromycin
- Control
Amoxicillin is already approved in European Union, United States, Canada for the following indications:
- Bacterial infections
- Respiratory tract infections
- Urinary tract infections
- Skin and soft tissue infections
- Ear, nose and throat infections
- Infections of the ear, nose, throat, genitourinary tract, skin and skin structure, and lower respiratory tract
- Bacterial infections
- Respiratory tract infections
- Urinary tract infections
- Skin and soft tissue infections
Find a Clinic Near You
Who Is Running the Clinical Trial?
National Institute of Allergy and Infectious Diseases (NIAID)
Lead Sponsor